Description of Peripheral Blood Perfusion by Laser Speckle Contrast Analysis (LASCA) in 'Early' versus 'Clinically Overt' Systemic Sclerosis in Routine Clinics.
Raynaud’s phenomenon
laser speckle contrast analysis (LASCA)
systemic sclerosis
‘clinically overt’ SSc
‘early’ SSc
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
27 Apr 2023
27 Apr 2023
Historique:
received:
15
04
2023
revised:
24
04
2023
accepted:
25
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
To investigate in an unselected, systemic sclerosis (SSc) cohort if baseline laser speckle contrast analysis (LASCA) peripheral blood perfusion (PBP) measurements differ between 'early' SSc (without skin involvement, or 'limited' SSc-LSSc) and 'clinically overt' SSc (with skin involvement, limited cutaneous SSc-LcSSc and diffuse cutaneous SSc-DcSSc) in routine setting. A group of twenty consecutive 'early' SSc patients and forty consecutive 'clinically overt' SSc patients (twenty LcSSc and twenty DcSSc) underwent clinical and LASCA examinations (to assess the peripheral blood perfusion [PBP] of both hands volar). No statistically significant difference in adjusted PBP was found in the 'early' versus the 'clinically overt' group ( This study with an unselected SSc population in daily routine, non-research setting, showed there was no difference in adjusted PBP at baseline between 'early' SSc and 'clinically overt' SSc when corrected for possible confounding factors. Interestingly a wide variation of individual datapoints were observed in each subset, which emphasizes the heterogeneity of SSc.
Identifiants
pubmed: 37174957
pii: diagnostics13091566
doi: 10.3390/diagnostics13091566
pmc: PMC10177938
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Research Foundation-Flanders (Belgium) (FWO)
ID : Research Foundation-Flanders (Belgium) (FWO) [1.8.029.20N]
Références
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Autoimmun Rev. 2018 Aug;17(8):775-780
pubmed: 29885540
Ann Rheum Dis. 2014 Jun;73(6):1181-5
pubmed: 23956248
Autoimmun Rev. 2020 Mar;19(3):102458
pubmed: 31927087
Lancet. 2023 Jan 28;401(10373):304-318
pubmed: 36442487
J Rheumatol. 2001 Jul;28(7):1573-6
pubmed: 11469464
J Biomed Opt. 1996 Apr;1(2):174-9
pubmed: 23014683
Mediterr J Rheumatol. 2019 Mar 28;30(1):48-50
pubmed: 32185343
J Rheumatol. 2016 Nov;43(11):2033-2041
pubmed: 27744392
Arthritis Rheum. 2013 Aug;65(8):1953-62
pubmed: 23666787
Front Pharmacol. 2019 Apr 04;10:293
pubmed: 31019461
Ann Rheum Dis. 2012 Oct;71(10):1636-9
pubmed: 22402146
Ann Rheum Dis. 2016 Jun;75(6):1263-4
pubmed: 27005682
Microvasc Res. 2018 Jan;115:28-33
pubmed: 28834709
Clin Rheumatol. 2020 Jan;39(1):69-75
pubmed: 31317425
Scand J Rheumatol. 2023 May;52(3):302-305
pubmed: 35880719
Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):119-123
pubmed: 34251314
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):109-14
pubmed: 23073231
Rheumatology (Oxford). 2021 Apr 6;60(4):1850-1857
pubmed: 33141226
Autoimmun Rev. 2017 Aug;16(8):787-795
pubmed: 28576600
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Nat Rev Rheumatol. 2010 Oct;6(10):578-87
pubmed: 20703220
Microvasc Res. 2016 May;105:119-24
pubmed: 26907637
Nat Rev Rheumatol. 2021 Nov;17(11):665-677
pubmed: 34561652
Rheumatology (Oxford). 2022 Nov 2;61(11):4384-4396
pubmed: 35176132
Scand J Rheumatol. 2016 Oct;45(5):408-11
pubmed: 26948487
J Pathol. 1992 Mar;166(3):255-63
pubmed: 1517881
Eur J Clin Invest. 2022 Jan;52(1):e13672
pubmed: 34424550